Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

• Status: Completed
• Trial end date: 2002-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria

• Signed informed consent

• Greater than 18 years of age

• Proof of breast cancer, multiple myeloma or prostate cancer

• Diagnosis of at least one cancer-related bone lesion

• If patient is of child-bearing potential, negative pregnancy test and on a medically recognized form of contraception

• ECOG performance status of 0,1 or 2

• Ability to read, understand and write English or Spanish language

• Normal renal function

• Corrected serum calcium equal to or greater than 8mg/dl Exclusion Criteria

• clinically symptomatic brain metastases

• hypersensitivity to Zometa or other bisphosphonates

• pregnant or lactating